Limited Anti-Tumor Activity of Combined BET and MEK Inhibition in Neuroblastoma

BACKGROUND: The treatment of high-risk neuroblastoma continues to present a formidable challenge to pediatric oncology. Previous studies have shown that BET (Bromodomain and extra-terminal) inhibitors can inhibit MYCN expression and suppress MYCN-amplified neuroblastoma in vivo. Furthermore, alterat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pediatr Blood Cancer
Autors principals: Healy, Jason R., Hart, Lori S., Shazad, Alexander L., Gagliardi, Maria E., Tsang, Matthew, Elias, Jimmy, Ruden, Jacob, Farrel, Alvin, Rokita, Jo Lynne, Li, Yimei, Wyce, Anastasia, Barbash, Olena, Batra, Vandana, Samanta, Minu, Maris, John M., Schnepp, Robert W.
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7188563/
https://ncbi.nlm.nih.gov/pubmed/32307821
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.28267
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars